Announced details
Severe dry eye and keratoconjunctival disorders caused by ocular graft-versus-host disease (ocular GVHD)
Commencement of first patient enrollment
Coordinating administrator and principal investigator for the physician-initiated specified clinical research study
Director of 新宿シティ眼科. Other information on its location, representative, business activities, capital and year of establishment is Not disclosed.
Clinical research plan number: jRCTs031250695
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | TLM-017 ophthalmic solution |
| Counterparty | Ogawa Yoko (小川葉子), Director of 新宿シティ眼科 |
| Counterparty overview | Director of 新宿シティ眼科. Other information on its location, representative, business activities, capital and year of establishment is Not disclosed. |
| Relationship with the Company | Coordinating administrator and principal investigator for the physician-initiated specified clinical research study |
| Launch date | 6 March 2026, commencement of first patient enrollment (actual) |
| Applicable area | Severe dry eye and keratoconjunctival disorders caused by ocular graft-versus-host disease (ocular GVHD) |
| Registration number and expiry date | Clinical research plan number: jRCTs031250695 |
| Usage history | Commencement of first patient enrollment |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To evaluate the safety and preliminary efficacy of TLM-017.